{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:53:28Z","timestamp":1786118008750,"version":"build-2736575974"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2026JJ81446"],"award-info":[{"award-number":["2026JJ81446"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug-resistant tuberculosis (DR-TB) is associated with low treatment success rates and increased mortality. Household contacts (HHCs) face an elevated risk of infection and disease progression due to prolonged exposure. Consequently, systematic screening and tuberculosis preventive treatment (TPT) are critical to interrupt transmission within households. However, screening practices and TPT regimens vary substantially across countries and settings worldwide, and the available evidence remains fragmented. This study aims to synthesize evidence on screening strategies and TPT regimens for HHCs of patients with DR-TB, identify implementation barriers and research gaps, and inform future contact management approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched nine databases including PubMed, Embase, and Web of Science. Each database was searched from inception to November 13, 2025. Eligible studies included observational studies (including cohort and cross-sectional studies), implementation studies, and randomized controlled trials reporting on screening approaches or TPT strategies among HHCs of patients with DR-TB. Data extraction was conducted in accordance with the Joanna Briggs Institute (JBI) methodological framework for scoping reviews, and reporting followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews (PRISMA-ScR) guidelines. Two reviewers independently extracted data using a standardized form, including study characteristics, screening strategies, diagnostic methods, TPT regimens, safety and adherence outcomes, and implementation-related factors. The findings were summarized descriptively and presented as a structured narrative synthesis organized by thematic domains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 26 studies were included. Most studies (20\/26) employed a sequential cascade screening strategy combining symptom assessment, imaging evaluation (when clinically indicated), and molecular or microbiological confirmation, often supplemented by tuberculin skin test (TST) or interferon-gamma release assays (IGRAs) for latent tuberculosis infection (LTBI) detection. Most studies were conducted in high TB burden low- and middle-income countries, particularly in Pakistan, South Africa, and China, with several multicenter studies spanning countries in Africa, Asia, and Latin America. Pediatric studies frequently incorporated gastric aspiration as an adjunct diagnostic method. TPT was implemented in 14 studies, with initiation rates ranging from 2% to 98.8%. Levofloxacin-based regimens were the predominant preventive treatment strategy. Compared with combination regimens, levofloxacin monotherapy generally achieved higher treatment completion rates (68.4%\u2013100% vs. 56%\u201370.3%). Children experienced fewer adverse events than adults (10% vs. 37%). Frequently reported implementation barriers included resource limitations, transportation difficulties, stigma, and poor treatment adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Screening and TPT for HHCs of patients with DR-TB were commonly implemented using sequential cascade screening approaches and levofloxacin-based preventive treatment regimens across diverse settings. Included studies generally reported acceptable treatment completion and safety outcomes, particularly for levofloxacin-based monotherapy, although implementation outcomes varied substantially across regions and populations. Resource limitations, stigma, transportation difficulties, and poor adherence were frequently reported as barriers to implementation. Given the substantial heterogeneity in study design, screening strategies, and implementation contexts, findings should be interpreted cautiously. Further research is needed to improve evidence on standardized screening approaches, regimen effectiveness, and implementation feasibility across different settings, particularly among high-risk populations such as young children and people living with human immunodeficiency virus (HIV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-14056-1","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:33:02Z","timestamp":1784885582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Screening and tuberculosis preventive treatment among household contacts of drug-resistant tuberculosis patients: a scoping review"],"prefix":"10.1186","volume":"26","author":[{"given":"Siling","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanghua","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"14056_CR1","unstructured":"World Health Organization. Global tuberculosis report 2025. 2025. https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2025. Accessed 4 Dec 2025."},{"key":"14056_CR2","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis Module 1: prevention-tuberculosis preventive treatment, second edition. 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240096196. Accessed 4 Dec 2025."},{"issue":"1","key":"14056_CR3","doi-asserted-by":"publisher","first-page":"2348505","DOI":"10.1080\/22221751.2024.2348505","volume":"13","author":"D Liu","year":"2024","unstructured":"Liu D, Huang F, Li Y, Mao L, He W, Wu S, et al. Transmission characteristics in Tuberculosis by WGS: nationwide cross-sectional surveillance in China. Emerg Microbes Infect. 2024;13(1):2348505.","journal-title":"Emerg Microbes Infect"},{"issue":"2","key":"14056_CR4","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/cid\/ciaa613","volume":"73","author":"SS Chiang","year":"2021","unstructured":"Chiang SS, Brooks MB, Jenkins HE, Rubenstein D, Seddon JA, Water BJ, et al. Concordance of Drug-resistance Profiles Between Persons With Drug-resistant Tuberculosis and Their Household Contacts: A Systematic Review and Meta-analysis. Clin Infect Dis. 2021;73(2):250\u201363.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"14056_CR5","doi-asserted-by":"publisher","first-page":"106198","DOI":"10.1016\/j.jinf.2024.106198","volume":"89","author":"TY Akalu","year":"2024","unstructured":"Akalu TY, Clements ACA, Gebreyohannes EA, Gilmour B, Alene KA. Prevalence of tuberculosis infection among contacts of drug-resistant tuberculosis patients: A systematic review and meta-analysis. J Infect. 2024;89(2):106198.","journal-title":"J Infect"},{"issue":"3\u20134","key":"14056_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.14745\/ccdr.v43i34a01","volume":"43","author":"S Kiazyk","year":"2017","unstructured":"Kiazyk S, Ball TB. Latent tuberculosis infection: An overview. Can Commun Dis Rep. 2017;43(3\u20134):62\u20136.","journal-title":"Can Commun Dis Rep"},{"issue":"4","key":"14056_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4103\/rid.RID-D-23-00012","volume":"10","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Li H, Ma Z, Wang J, Yin X. Advances in imaging studies of active pulmonary tuberculosis. Radiol Infect Dis. 2023;10(4):125\u20139.","journal-title":"Radiol Infect Dis"},{"key":"14056_CR8","unstructured":"European Centre for Disease Prevention and Control, WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2022\u20132024 data. 2024. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/TB_Surveillance_Report_2024.pdf. Accessed 4 Dec 2025."},{"issue":"1","key":"14056_CR9","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1164\/rccm.202410-2096ST","volume":"211","author":"JJ Saukkonen","year":"2025","unstructured":"Saukkonen JJ, Duarte R, Munsiff SS, Winston CA, Mammen MJ, Abubakar I, et al. Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2025;211(1):e1\u201334.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"14056_CR10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.5588\/ijtldopen.24.0348","volume":"1","author":"K Bennani","year":"2024","unstructured":"Bennani K, Van Den Boom M, ElMedrek MG, Hutin Y. Progress in programmatic management of drug-resistant TB, WHO Eastern Mediterranean Region, 2018\u20132023. IJTLD Open. 2024;1(9):404\u201310.","journal-title":"IJTLD Open"},{"issue":"1","key":"14056_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12890-025-03906-4","volume":"25","author":"MM Mpimbaza","year":"2025","unstructured":"Mpimbaza MM, Migisha R, Twesigomwe G, Bajunirwe F. Missed opportunity for tuberculosis screening and prevention and the associated factors among child contacts in rural southwestern Uganda. BMC Pulm Med. 2025;25(1):86.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"14056_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1183\/09031936.00070812","volume":"41","author":"GJ Fox","year":"2013","unstructured":"Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2013;41(1):140\u201356.","journal-title":"Eur Respir J"},{"issue":"8","key":"14056_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s12098-023-04969-z","volume":"91","author":"A Tayal","year":"2024","unstructured":"Tayal A, Kabra SK. Tuberculosis Preventive Treatment. Indian J Pediatr. 2024;91(8):823\u20139.","journal-title":"Indian J Pediatr"},{"key":"14056_CR14","unstructured":"World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. 2018. https:\/\/apps.who.int\/iris\/handle\/10665\/260233. Accessed 4 Dec 2025."},{"issue":"24","key":"14056_CR15","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa2314318","volume":"391","author":"AC Hesseling","year":"2024","unstructured":"Hesseling AC, Purchase SE, Martinson NA, Fairlie L, Schaaf HS, Brigden J, et al. Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis. N Engl J Med. 2024;391(24):2315\u201326.","journal-title":"N Engl J Med"},{"issue":"2","key":"14056_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cmi.2023.09.015","volume":"30","author":"G Zhou","year":"2024","unstructured":"Zhou G, Luo S, He J, Chen N, Zhang Y, Cai S, et al. Effectiveness and safety of tuberculosis preventive treatment for contacts of patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Clin Microbiol Infect. 2024;30(2):189\u201396.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"14056_CR17","doi-asserted-by":"publisher","first-page":"EVIDoa2400190","DOI":"10.1056\/EVIDoa2400190","volume":"4","author":"T Duong","year":"2025","unstructured":"Duong T, Brigden J, Simon Schaaf H, Garden F, Marais BJ, Anh Nguyen T, et al. A Meta-Analysis of Levofloxacin for Contacts of Multidrug-Resistant Tuberculosis. NEJM Evid. 2025;4(1):EVIDoa2400190.","journal-title":"NEJM Evid"},{"key":"14056_CR18","doi-asserted-by":"publisher","first-page":"107849","DOI":"10.1016\/j.ijid.2025.107849","volume":"155","author":"A Matteelli","year":"2025","unstructured":"Matteelli A, Lovatti S, Rossi B, Rossi L. Update on multidrug-resistant tuberculosis preventive therapy toward the global tuberculosis elimination. Int J Infect Dis. 2025;155:107849.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"14056_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","volume":"18","author":"Z Munn","year":"2018","unstructured":"Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):143.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"14056_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19\u201332.","journal-title":"Int J Soc Res Methodol"},{"issue":"10","key":"14056_CR21","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","volume":"18","author":"MDJ Peters","year":"2020","unstructured":"Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119\u201326.","journal-title":"JBI Evid Synth"},{"key":"14056_CR22","unstructured":"Joanna Briggs Institute. Scoping reviews. 2024. https:\/\/jbi-global-wiki.refined.site\/space\/MANUAL\/355862497\/10.+Scoping+reviews. Accessed 6 Dec 2025."},{"issue":"7","key":"14056_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467\u201373.","journal-title":"Ann Intern Med"},{"key":"14056_CR24","unstructured":"Joanna Briggs Institute. Critical Appraisal Tools. https:\/\/jbi.global\/critical-appraisal-tools. Accessed 20 May 2026."},{"issue":"3","key":"14056_CR25","doi-asserted-by":"publisher","first-page":"478","DOI":"10.11124\/JBIES-22-00125","volume":"21","author":"TH Barker","year":"2023","unstructured":"Barker TH, Stone JC, Sears K, Klugar M, Leonardi-Bee J, Tufanaru C, et al. Revising the JBI quantitative critical appraisal tools to improve their applicability: an overview of methods and the development process. JBI Evid Synth. 2023;21(3):478\u201393.","journal-title":"JBI Evid Synth"},{"key":"14056_CR26","doi-asserted-by":"publisher","first-page":"108084","DOI":"10.1016\/j.cct.2025.108084","volume":"158","author":"MA Kendall","year":"2025","unstructured":"Kendall MA, Hughes MD, Kim S, Aaron LA, Naini L, Suryavanshi N, et al. Protecting households on exposure to newly diagnosed index multidrug-resistant tuberculosis patients: Study protocol for the PHOENIx phase 3 clinical trial. Contemp Clin Trials. 2025;158:108084.","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"14056_CR27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1186\/s13063-018-3070-0","volume":"19","author":"JA Seddon","year":"2018","unstructured":"Seddon JA, Garcia-Prats AJ, Purchase SE, Osman M, Demers AM, Hoddinott G, et al. Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). Trials. 2018;19(1):693.","journal-title":"Trials"},{"issue":"3","key":"14056_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/cid\/ciz235","volume":"70","author":"A Gupta","year":"2020","unstructured":"Gupta A, Swindells S, Kim S, Hughes MD, Naini L, Wu X, et al. Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease. Clin Infect Dis. 2020;70(3):425\u201335.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"14056_CR29","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/00006454-199906000-00004","volume":"18","author":"HS Schaaf","year":"1999","unstructured":"Schaaf HS, Vermeulen HA, Gie RP, Beyers N, Donald PR. Evaluation of young children in household contact with adult multidrug-resistant pulmonary tuberculosis cases. Pediatr Infect Dis J. 1999;18(6):494\u2013500.","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"14056_CR30","doi-asserted-by":"publisher","first-page":"ofad087","DOI":"10.1093\/ofid\/ofad087","volume":"10","author":"I Apolisi","year":"2023","unstructured":"Apolisi I, Cox H, Tyeku N, Daniels J, Mathee S, Cariem R, et al. Tuberculosis Diagnosis and Preventive Monotherapy Among Children and Adolescents Exposed to Rifampicin-Resistant Tuberculosis in the Household. Open Forum Infect Dis. 2023;10(3):ofad087.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"14056_CR31","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3201\/eid2703.203916","volume":"27","author":"AA Malik","year":"2021","unstructured":"Malik AA, Gandhi NR, Lash TL, Cranmer LM, Omer SB, Ahmed JF, et al. Effectiveness of Preventive Therapy for Persons Exposed at Home to Drug-Resistant Tuberculosis, Karachi, Pakistan. Emerg Infect Dis. 2021;27(3):805\u201312.","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"14056_CR32","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1136\/archdischild-2018-315411","volume":"104","author":"H Huerga","year":"2019","unstructured":"Huerga H, Sanchez-Padilla E, Melikyan N, Atshemyan H, Hayrapetyan A, Ulumyan A, et al. High prevalence of infection and low incidence of disease in child contacts of patients with drug-resistant tuberculosis: a prospective cohort study. Arch Dis Child. 2019;104(7):622\u20138.","journal-title":"Arch Dis Child"},{"issue":"8","key":"14056_CR33","doi-asserted-by":"publisher","first-page":"ofaf425","DOI":"10.1093\/ofid\/ofaf425","volume":"12","author":"T Duong","year":"2025","unstructured":"Duong T, Brigden J, Purchase SE, Martinson NA, Fairlie L, Staples S, et al. Factors Predictive of Early Discontinuation of Preventive Treatment in Children With Household Exposure to Multidrug-resistant Tuberculosis. Open Forum Infect Dis. 2025;12(8):ofaf425.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"14056_CR34","first-page":"195","volume":"45","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Zhou M, Peng J, Duan Q, Chen J, Zhou M, et al. Analysis of household transmission of multidrug-resistant pulmonary tuberculosis. Chin J Antituberc. 2023;45(2):195\u20139.","journal-title":"Chin J Antituberc"},{"issue":"5","key":"14056_CR35","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1542\/peds.109.5.765","volume":"109","author":"HS Schaaf","year":"2002","unstructured":"Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics. 2002;109(5):765\u201371.","journal-title":"Pediatrics"},{"issue":"5","key":"14056_CR36","doi-asserted-by":"publisher","first-page":"520","DOI":"10.5588\/ijtld.13.0593","volume":"18","author":"F Amanullah","year":"2014","unstructured":"Amanullah F, Ashfaq M, Khowaja S, Parekh A, Salahuddin N, Lotia-Farrukh I, et al. High tuberculosis prevalence in children exposed at home to drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2014;18(5):520\u20137.","journal-title":"Int J Tuberc Lung Dis"},{"key":"14056_CR37","doi-asserted-by":"publisher","first-page":"100561","DOI":"10.1016\/j.jctube.2025.100561","volume":"41","author":"Z Shi","year":"2025","unstructured":"Shi Z, Peng J, Li X, Fu X, Zou L, Chen Q, et al. Mycobacterium tuberculosis infection status and associated factors among household close contacts of rifampicin-resistant pulmonary tuberculosis patients: A single-center cross-sectional study. J Clin Tuberc Other Mycobact Dis. 2025;41:100561.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"6","key":"14056_CR38","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/cid\/ciad301","volume":"77","author":"S Krishnan","year":"2023","unstructured":"Krishnan S, Wu X, Kim S, McIntire K, Naini L, Hughes MD, et al. 1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis. Clin Infect Dis. 2023;77(6):892\u2013900.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"14056_CR39","first-page":"172","volume":"45","author":"H Yang","year":"2023","unstructured":"Yang H, Ma J, Ren F, Li R, Wu Y, Zhang Y. Clinical characteristics of household contacts developing active pulmonary tuberculosis among 15 patients with drug-resistant pulmonary tuberculosis. Chin J Antituberc. 2023;45(2):172\u201380.","journal-title":"Chin J Antituberc"},{"issue":"9","key":"14056_CR40","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1093\/cid\/ciz502","volume":"70","author":"AA Malik","year":"2020","unstructured":"Malik AA, Fuad J, Siddiqui S, Amanullah F, Jaswal M, Barry Z, et al. Tuberculosis Preventive Therapy for Individuals Exposed to Drug-resistant Tuberculosis: Feasibility and Safety of a Community-based Delivery of Fluoroquinolone-containing Preventive Regimen. Clin Infect Dis. 2020;70(9):1958\u201365.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"14056_CR41","first-page":"495","volume":"29","author":"Z Iqbal","year":"2023","unstructured":"Iqbal Z, Rameen Y, Anjum T, Hidayat U, Younis F. Infection and Disease among household contacts of Multidrug Resistant Tuberculosis Patients in Khyber Pakhtunkhwa. Pakistan J Chest Med. 2023;29(4):495\u2013500.","journal-title":"Pakistan J Chest Med"},{"key":"14056_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jctube.2017.01.004","volume":"7","author":"E Qadeer","year":"2017","unstructured":"Qadeer E, Fatima R, Haq MU, Yaqoob A, Kyaw NTT, Shah S, et al. Yield of facility-based verbal screening amongst household contacts of patients with multi-drug resistant tuberculosis in Pakistan. J Clin Tuberc Other Mycobact Dis. 2017;7:22\u20137.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"1","key":"14056_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijtb.2020.09.030","volume":"68","author":"BJ Shadrach","year":"2021","unstructured":"Shadrach BJ, Kumar S, Deokar K, Singh GV, Hariharan, Goel R. A study of multidrug resistant tuberculosis among symptomatic household contacts of MDR-TB patients. Indian J Tuberc. 2021;68(1):25\u201331.","journal-title":"Indian J Tuberc"},{"issue":"9","key":"14056_CR44","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.apjtm.2016.07.017","volume":"9","author":"A Javaid","year":"2016","unstructured":"Javaid A, Khan MA, Khan MA, Mehreen S, Basit A, Khan RA, et al. Screening outcomes of household contacts of multidrug-resistant tuberculosis patients in Peshawar, Pakistan. Asian Pac J Trop Med. 2016;9(9):909\u201312.","journal-title":"Asian Pac J Trop Med"},{"key":"14056_CR45","first-page":"101704","volume":"63","author":"B Tsogt","year":"2025","unstructured":"Tsogt B, Sambuu T, Purevsuren Y, Munkhbaatar S, Batsuren P, Khandaa OE, et al. Multidrug-resistant tuberculosis household contact screening and management by community healthcare workers in Mongolia: a prospective implementation study. Lancet Reg Health West Pac. 2025;63:101704.","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"14056_CR46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/tropicalmed5010002","volume":"5","author":"NTT Kyaw","year":"2019","unstructured":"Kyaw NTT, Sithu A, Satyanarayana S, Kumar AMV, Thein S, Thi AM, et al. Outcomes of Community-Based Systematic Screening of Household Contacts of Patients with Multidrug-Resistant Tuberculosis in Myanmar. Trop Med Infect Dis. 2019;5(1):2.","journal-title":"Trop Med Infect Dis"},{"issue":"10","key":"14056_CR47","doi-asserted-by":"publisher","first-page":"748","DOI":"10.5588\/ijtld.23.0066","volume":"27","author":"ML Rekart","year":"2023","unstructured":"Rekart ML, Aung A, Cullip T, Mulanda W, Mun L, Pirmahmadzoda B, et al. Household drug-resistant TB contact tracing in Tajikistan. Int J Tuberc Lung Dis. 2023;27(10):748\u201353.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"24","key":"14056_CR48","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1056\/NEJMoa2314325","volume":"391","author":"GJ Fox","year":"2024","unstructured":"Fox GJ, Nhung NV, Cam Binh N, Hoa NB, Garden FL, Benedetti A, et al. Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis in Vietnam. N Engl J Med. 2024;391(24):2304\u201314.","journal-title":"N Engl J Med"},{"issue":"3","key":"14056_CR49","doi-asserted-by":"publisher","first-page":"e0283290","DOI":"10.1371\/journal.pone.0283290","volume":"18","author":"S Kim","year":"2023","unstructured":"Kim S, Hesseling AC, Wu X, Hughes MD, Shah NS, Gaikwad S, et al. Factors associated with prevalent Mycobacterium tuberculosis infection and disease among adolescents and adults exposed to rifampin-resistant tuberculosis in the household. PLoS ONE. 2023;18(3):e0283290.","journal-title":"PLoS ONE"},{"issue":"9","key":"14056_CR50","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.5588\/ijtld.18.0163","volume":"22","author":"S Swindells","year":"2018","unstructured":"Swindells S, Gupta A, Kim S, Hughes MD, Sanchez J, Mave V, et al. Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300\/I2003). Int J Tuberc Lung Dis. 2018;22(9):1016\u201322.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"14056_CR51","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1093\/cid\/ciaa327","volume":"72","author":"AA Malik","year":"2021","unstructured":"Malik AA, Becerra MC, Lash TL, Cranmer LM, Omer SB, Fuad J, et al. Risk Factors for Adverse Events in Household Contacts Prescribed Preventive Treatment for Drug-resistant Tuberculosis Exposure. Clin Infect Dis. 2021;72(10):1709\u201315.","journal-title":"Clin Infect Dis"},{"key":"14056_CR52","unstructured":"World Health Organization. Global tuberculosis report 2024. 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240101531. Accessed 20 May 2026."},{"key":"14056_CR53","doi-asserted-by":"crossref","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. 2020. https:\/\/www.who.int\/publications\/i\/item\/who-consolidated-guidelines-on-tuberculosis-module-1-prevention-tuberculosis-preventive-treatment. Accessed 20 May 2026.","DOI":"10.30978\/TB2021-2-86"},{"key":"14056_CR54","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 2: screening: systematic screening for tuberculosis disease. 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240022676. Accessed 16 Dec 2025."},{"issue":"1","key":"14056_CR55","doi-asserted-by":"publisher","first-page":"e0169539","DOI":"10.1371\/journal.pone.0169539","volume":"12","author":"SK Sharma","year":"2017","unstructured":"Sharma SK, Vashishtha R, Chauhan LS, Sreenivas V, Seth D. Comparison of TST and IGRA in Diagnosis of Latent Tuberculosis Infection in a High TB-Burden Setting. PLoS ONE. 2017;12(1):e0169539.","journal-title":"PLoS ONE"},{"key":"14056_CR56","unstructured":"Centers for Disease Control and Prevention (CDC). Clinical Testing Guidance for Tuberculosis: Interferon Gamma Release Assay. 2024. https:\/\/www.cdc.gov\/tb\/hcp\/testing-diagnosis\/interferon-gamma-release-assay.html. Accessed 16 Dec 2025."},{"issue":"18","key":"14056_CR57","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.3390\/diagnostics15182343","volume":"15","author":"MA Tobaiqi","year":"2025","unstructured":"Tobaiqi MA, Alshamrani MN, Sriram S, Mahmoud AB, Fadlalmola HA, Albadrani M. Interferon-Gamma Release Assays Versus Tuberculin Skin Test for Active Tuberculosis Diagnosis: A Systematic Review and Diagnostic Meta-Analysis. Diagnostics (Basel). 2025;15(18):2343.","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"14056_CR58","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/cid\/cit643","volume":"58","author":"NS Shah","year":"2014","unstructured":"Shah NS, Yuen CM, Heo M, Tolman AW, Becerra MC. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2014;58(3):381\u201391.","journal-title":"Clin Infect Dis"},{"issue":"10228","key":"14056_CR59","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0140-6736(20)30166-5","volume":"395","author":"L Martinez","year":"2020","unstructured":"Martinez L, Cords O, Horsburgh CR, Andrews JR, Pediatric TB, Contact Studies Consortium. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet. 2020;395(10228):973\u201384.","journal-title":"Lancet"},{"issue":"5","key":"14056_CR60","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1093\/cid\/ciaf284","volume":"81","author":"SE Purchase","year":"2025","unstructured":"Purchase SE, Brigden J, Seddon JA, Martinson NA, Fairlie L, Staples S, et al. Risk of Tuberculosis Infection in Young Children Exposed to Multidrug-resistant Tuberculosis in the TB-CHAMP Multi-site Randomized Controlled Trial. Clin Infect Dis. 2025;81(5):e401\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"14056_CR61","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/INF.0000000000003338","volume":"41","author":"J Jia","year":"2022","unstructured":"Jia J, Chen D, Liu L, Siddiqui MJ, Yang F, Zhu Y, et al. Prevalence of Latent Tuberculosis Infection Among Healthy Young Children and Adolescents and a Two-step Approach for the Diagnosis of Tuberculosis Infection in Chengdu, China. Pediatr Infect Dis J. 2022;41(1):6\u201311.","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"14056_CR62","doi-asserted-by":"publisher","first-page":"e097935","DOI":"10.1136\/bmjopen-2024-097935","volume":"15","author":"D Nair","year":"2025","unstructured":"Nair D, Thekkur P, Thiagesan R, Vyas A, Paul S, Mishra BK, et al. Implementing timeliness metrics for household contact tracing and TB preventive treatment through TB champions in the public sector, India: an explanatory mixed-methods study. BMJ Open. 2025;15(11):e097935.","journal-title":"BMJ Open"},{"issue":"1","key":"14056_CR63","doi-asserted-by":"publisher","first-page":"41","DOI":"10.5588\/ijtldopen.23.0545","volume":"1","author":"D Nair","year":"2024","unstructured":"Nair D, Thekkur P, Mbithi I, Khogali M, Zachariah R, Dar Berger S, et al. Timeliness metrics for screening and preventing TB in household contacts of pulmonary TB patients in Kenya. IJTLD Open. 2024;1(1):41\u20139.","journal-title":"IJTLD Open"},{"issue":"12","key":"14056_CR64","doi-asserted-by":"publisher","first-page":"e0295580","DOI":"10.1371\/journal.pone.0295580","volume":"18","author":"B Jamil","year":"2023","unstructured":"Jamil B, Nair D, Thekkur P, Laeeq N, Adil A, Khogali M, et al. Feasibility, enablers and challenges of using timeliness metrics for household contact tracing and TB preventive therapy in Pakistan. PLoS ONE. 2023;18(12):e0295580.","journal-title":"PLoS ONE"},{"issue":"1","key":"14056_CR65","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/tropicalmed9010007","volume":"9","author":"P Mahajan","year":"2023","unstructured":"Mahajan P, Soundappan K, Singla N, Mehta K, Nuken A, Thekkur P, et al. Test and Treat Model for Tuberculosis Preventive Treatment among Household Contacts of Pulmonary Tuberculosis Patients in Selected Districts of Maharashtra: A Mixed-Methods Study on Care Cascade, Timeliness, and Early Implementation Challenges. Trop Med Infect Dis. 2023;9(1):7.","journal-title":"Trop Med Infect Dis"},{"key":"14056_CR66","unstructured":"Chinese Center for Disease Control and Prevention. Technical Guidelines for Tuberculosis Prevention and Control in China. 2022. https:\/\/tb.chinacdc.cn\/xxjlg\/202111\/W020211119672904030470.pdf. Accessed 16 Dec 2025."},{"key":"14056_CR67","doi-asserted-by":"publisher","first-page":"100518","DOI":"10.1016\/j.puhip.2024.100518","volume":"8","author":"P Giridharan","year":"2024","unstructured":"Giridharan P, Suseela RP, Zangpo T, Joshi RB, Cader M, Isbaniah F, et al. Tuberculosis preventive treatment in eight SEAR countries - Current practices, implementation challenges and operations research priorities. Public Health Pract (Oxf). 2024;8:100518.","journal-title":"Public Health Pract (Oxf)"},{"key":"14056_CR68","unstructured":"World Health Organization. Global tuberculosis report 2024. 2024. https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024. Accessed 16 Dec 2025."},{"issue":"6","key":"14056_CR69","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/cid\/ciaf088","volume":"80","author":"MR Jaswal","year":"2025","unstructured":"Jaswal MR, Martinez L, Brooks M, Farooq S, Safdar N, Shah JA, et al. Tuberculosis-Preventive Treatment for Household Contacts at Health Facility and Community Settings in Pakistan. Clin Infect Dis. 2025;80(6):1290\u20132.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"14056_CR70","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","volume":"200","author":"P Nahid","year":"2019","unstructured":"Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS\/CDC\/ERS\/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019;200(10):e93\u2013142.","journal-title":"Am J Respir Crit Care Med"},{"key":"14056_CR71","first-page":"101666","volume":"61","author":"T Hasan","year":"2025","unstructured":"Hasan T, Thu Anh N, Binh Hoa N, Viet Nhung N, Yapa HM, Graham SM, et al. Evaluating the cost-effectiveness of levofloxacin therapy for household contacts of multidrug-resistant tuberculosis in Vietnam. Lancet Reg Health West Pac. 2025;61:101666.","journal-title":"Lancet Reg Health West Pac"},{"issue":"8","key":"14056_CR72","doi-asserted-by":"publisher","first-page":"e1205","DOI":"10.1016\/S2214-109X(23)00251-6","volume":"11","author":"T Ryckman","year":"2023","unstructured":"Ryckman T, Weiser J, Gombe M, Turner K, Soni P, Tarlton D, et al. Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysis. Lancet Glob Health. 2023;11(8):e1205\u201316.","journal-title":"Lancet Glob Health"},{"issue":"6","key":"14056_CR73","doi-asserted-by":"publisher","first-page":"100963","DOI":"10.1016\/j.lanmic.2024.100963","volume":"6","author":"L Carratal\u00e0-Castro","year":"2025","unstructured":"Carratal\u00e0-Castro L, Munguambe S, Saavedra-Cervera B, de Haas P, Kay A, Marcy O, et al. Performance of stool-based molecular tests and processing methods for paediatric tuberculosis diagnosis: a systematic review and meta-analysis. Lancet Microbe. 2025;6(6):100963.","journal-title":"Lancet Microbe"},{"key":"14056_CR74","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ijregi.2022.06.004","volume":"4","author":"G Seid","year":"2022","unstructured":"Seid G, Alemu A, Tsedalu T, Dagne B. Value of urine-based lipoarabinomannan (LAM) antigen tests for diagnosing tuberculosis in children: systematic review and meta-analysis. IJID Reg. 2022;4:97\u2013104.","journal-title":"IJID Reg"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14056-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14056-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14056-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:02:33Z","timestamp":1786028553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-14056-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14056"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-14056-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required for this study because it was a scoping review based on secondary analysis of previously published data. All included studies were publicly available publications and had obtained ethical approval in their original studies.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1438"}}